

Applicants: Sharon Cohen-Vered, et al.
Serial No.: 10/758,572
Filed : January 14, 2004
Page : 2

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A pharmaceutical composition comprising
an aqueous carrier;
from 0.1 mg/ml to 20 mg/ml of the composition of a
pharmaceutically acceptable salt of a peptide having the
structural formula
NH₂-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu
Glu Trp Ile Gly-COOH (SEQ ID NO:1); and
a substituted β -cyclodextrin in an amount effective to
dissolve the peptide in the aqueous carrier,
wherein the pharmaceutical composition has a pH between 4 and
9.
2. (Original) The pharmaceutical composition of claim 1, wherein
the concentration of the salt of the peptide is at least 0.5
mg/ml.
3. (Original) The pharmaceutical composition of claim 2, wherein
the concentration of the salt of the peptide is from 0.5
mg/ml to 10 mg/ml.
4. (Original) The pharmaceutical composition of claim 3, wherein
the concentration of the salt of the peptide is from 0.5
mg/ml to 2.5 mg/ml.
5. (Previously Presented) The pharmaceutical composition of claim
1 wherein the composition has a pH between 6.5 and 8.5.
6. (Original) The pharmaceutical composition of claim 5, wherein
the composition has a pH between 7.5 and 8.5.

Applicants: Sharon Cohen-Vered, et al.
Serial No.: 10/758,572
Filed : January 14, 2004
Page : 3

7. (Previously Presented) The pharmaceutical composition claim 1 wherein the pharmaceutically acceptable salt is an acetate salt.
8. (Previously Presented) The pharmaceutical composition of claim 1 wherein the substituted β -cyclodextrin is a hydroxypropyl, a sulfobutyl ether, or a sulfopropyl ether substituted β -cyclodextrin.
9. (Original) The pharmaceutical composition of claim 8, wherein the substituted β -cyclodextrin is a sulfobutyl ether substituted β -cyclodextrin.
10. (Original) The pharmaceutical composition of claim 7, wherein the substituted β -cyclodextrin is hepta-(sulfobutyl ether)- β -cyclodextrin.
11. (Previously Presented) The pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable buffer in an amount and of a type suitable to make the pH of the pharmaceutical composition in the range of 4-9.
12. (Currently Amended) A pharmaceutical composition comprising
an aqueous carrier;
from 0.1 mg/ml to 20 mg/ml of the composition of an acetate salt of a peptide having the structural formula
NH₂-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu
Trp Ile Gly-COOH (SEQ ID NO:1); and
from 70 mg/ml to 170 mg/ml of the composition of hepta-(sulfobutyl ether)- β -cyclodextrin,
wherein the peptide and the hepta-(sulfobutyl ether)- β -cyclodextrin are dissolved in the aqueous carrier; and
wherein the pharmaceutical composition has a pH between 6.5

Applicants: Sharon Cohen-Vered, et al.
Serial No.: 10/758,572
Filed : January 14, 2004
Page : 4

and 8.5.

13. (Original) The pharmaceutical composition of claim 12, wherein the concentration of the acetate salt of the peptide is at least 0.5 mg/ml.
14. (Original) The pharmaceutical composition of claim 13, wherein the concentration of the acetate salt of the peptide is from 0.5 mg/ml to 10 mg/ml.
15. (Original) The pharmaceutical composition of claim 13, wherein the concentration of the acetate salt of the peptide is from 0.5 to 2.5 mg/ml.
16. (Currently Amended) The pharmaceutical composition of claim 13, wherein the concentration of hepta-(sulfobutyl ether)- β -cyclodextrin is 120 mg/ml, and wherein the pH of the pharmaceutical composition is between 7.5 and 8.5.
17. (Original) The pharmaceutical composition of claim 16, wherein the concentration of the acetate salt of the peptide is 1.0 mg/ml.
18. (Original) The pharmaceutical composition of claim 16, wherein the concentration of the acetate salt of the peptide is 2.5 mg/ml.
19. (Withdrawn) A method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition of claim 1 in an amount effective to alleviate the symptoms of SLE in the human subject.

Applicants: Sharon Cohen-Vered, et al.
Serial No.: 10/758,572
Filed : January 14, 2004
Page : 5

Claim 20. (Canceled)

21. (Withdrawn) A process for manufacturing the pharmaceutical composition of claim 1 comprising the steps of:

- a) preparing a solution of a substituted β -cyclodextrin in an aqueous carrier at a predetermined concentration;
- b) adding a predetermined amount of a pharmaceutically acceptable salt of the peptide NH₂-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH (SEQ ID NO:1) to the solution of step a);
- c) adjusting the pH of the solution of step b) until the peptide dissolves in the solution; and
- d) if necessary, adjusting the pH of the solution of step c) to a pH of 4-9, thereby manufacturing the pharmaceutical composition.

Claims 22-30. (Canceled)

31. (Previously Presented) A pharmaceutical composition prepared by the process of claim 21.

32. (Withdrawn) A process of lyophilizing the pharmaceutical composition of claim 2, comprising the steps of:

- a) lowering the temperature of the pharmaceutical composition to -40°C;
- b) holding the temperature at -40°C for a predetermined time;
- c) raising the temperature of the solution to 20°C;
- d) holding the temperature at 20°C for a predetermined time; and
- e) reducing the pressure and holding the temperature at 20°C for a predetermined time, thereby lyophilizing the pharmaceutical composition.

Applicants: Sharon Cohen-Vered, et al.
Serial No.: 10/758,572
Filed : January 14, 2004
Page : 6

Claims 33-40. (Canceled)

41. (Withdrawn) The process of claim 32, wherein
step a) is performed within 2 hours;
step b) is performed within 3 hours;
step c) is performed over 13 hours and at a pressure of
110µbar;
step d) is performed over 13 hours and at a pressure of
110µbar; and
step e) is performed over 5 hours and the pressure is reduced
to 10µbar.

42. (Previously Presented) A lyophilized pharmaceutical composition
prepared by the process of claim 32.

43. (Withdrawn) A process of lyophilizing the pharmaceutical
composition of claim 2, comprising the steps of:

- a) lowering the temperature of the pharmaceutical composition
to -45°C;
- b) holding the temperature at -45°C for a predetermined time;
- c) raising the temperature of the solution to -20°C;
- d) raising the temperature of the solution to 25°C; and
- e) holding the temperature at 25°C for a predetermined time,
thereby lyophilizing the pharmaceutical composition.

Claims 44-51. (Canceled)

52. (Withdrawn) The process of claim 43, wherein
step a) is performed within 6 hours;
step b) is performed within 3 hours;
step c) is performed over 19 hours and at a pressure of
150µbar;
step d) is performed over 13 hours and at a pressure of

Applicants: Sharon Cohen-Vered, et al.
Serial No.: 10/758,572
Filed : January 14, 2004
Page : 7

150µbar; and
step e) is performed over 8 hours and at a pressure of
150µbar.

53. (Original) A lyophilized pharmaceutical composition prepared
by the process of claim 43.

Claims 54-56. (Canceled)

57. (Original) A lyophilized pharmaceutical composition comprising
a pharmaceutically acceptable salt of a peptide having the
structural formula

NH₂-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu
Glu Trp Ile Gly-COOH (SEQ ID NO:1); and
a substituted β-cyclodextrin.

58. (Currently Amended) A packaged pharmaceutical composition
comprised of:

a packaging material; and

~~a predetermined amount of the~~ lyophilized pharmaceutical
composition of claim 57.

59. (Currently Amended) The lyophilized pharmaceutical composition
of claim 53, wherein the water content of the pharmaceutical
composition is less than 5%.

60. (Currently Amended) The lyophilized pharmaceutical composition
of claim 59, wherein the water content of the pharmaceutical
composition is less than 4.0%.

Applicants: Sharon Cohen-Vered, et al.
Serial No.: 10/758,572
Filed : January 14, 2004
Page : 8

61. (Currently Amended) The lyophilized pharmaceutical composition of claim 60, wherein the water content of the pharmaceutical composition is less than 3.5%.